identity and at least one of the functional characteristics of the living cells useful in immunotherapy.

20. The method of claim 19 further comprising placing the formulated cells in a flexible container or syringe prior to transporting.

21. The method of claim 19 wherein the live cells are CD4+ cells and when activated are Th1 cells.

22. The method of claim 21 wherein the Th1 cells are activated by immobilized monoclonal antibodies, wherein the monoclonal antibodies are cross-linked.

23. The method of claim 19 wherein the live cells in the composition express CD40L after transportation and removal from storage temperature in an amount of at least about 80% relative to the expression of CD40L at the time of formulation.

24. The method of claim 19 wherein the cells in the composition secrete IFN-γ after transportation and removal from storage temperature in an amount of at least about 80% compared to the levels at the time of formulation.

25. The method of claim 24 wherein the secretion of IFN-γ after transportation and storage is recovered after incubation at 37°C for at least 24 hours.

26. The method of claim 19 wherein the live cells in the non-nutritive buffer are at the storage temperature for at least about 72 hours.

~~27. A method of administering immunotherapy to a patient comprising administering a composition comprising living cells formulated in non-nutritive buffer, wherein the composition has been stored for greater than about six hours in the non-nutritive buffer, wherein the living cells maintain their identity and at least one of the functional characteristics of the cells that defined the living cells prior to formulation in the non-nutritive buffer, the living cells useful in immunotherapy.~~

~~28. The method of claim 27 wherein the live cells are activated Th1 cells.~~

~~29. The method of claim 28 wherein the functional characteristic is expression of CD40L, FasL, perforin and granzyme B, expression of costimulatory molecules, expression of adhesion molecules, secretion of cytokines, chemokines or combinations thereof.~~

~~30. The method of claim 28 wherein the live cells in the composition express CD40L after storage in an amount of at least about 80% relative to the expression of CD40L at the time of formulation.~~

~~31. The method of claim 28 wherein the cells in the composition secrete IFN-γ after storage in an amount of at least about 80% compared to the levels at the time of formulation and wherein the secretion of IFN-γ after storage is recovered after incubation at 37°C for at least 24 hours.~~

~~32. The method of claim 28 wherein the live cells in the non-nutritive buffer are stored for at least about 72 hours.~~